OAG
ABBV icon

Orbis Allan Gray’s AbbVie ABBV Stock Holding History

Orbis Allan Gray’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-347,007
Closed -$56.3M – 74
2022
Q1 		$56.3M Sell
347,007
-137,297
-28% -$19.9M 0.41% 38
2021
Q4 		$65.6M Sell
484,304
-2,522,350
-84% -$298M 0.49% 34
2021
Q3 		$324M Sell
3,006,654
-3,625,731
-55% -$414M 2.23% 18
2021
Q2 		$747M Sell
6,632,385
-184,398
-3% -$20.8M 4.72% 6
2021
Q1 		$738M Sell
6,816,783
-1,368,003
-17% -$146M 5.28% 7
2020
Q4 		$877M Sell
8,184,786
-1,086,401
-12% -$104M 6.35% 4
2020
Q3 		$812M Sell
9,271,187
-1,272,552
-12% -$120M 6.39% 4
2020
Q2 		$1.04B Sell
10,543,739
-2,996,311
-22% -$264M 7.79% 3
2020
Q1 		$1.03B Sell
13,540,050
-2,558,246
-16% -$218M 9.82% 2
2019
Q4 		$1.43B Sell
16,098,296
-1,126,356
-7% -$93.5M 9.95% 3
2019
Q3 		$1.3B Buy
17,224,652
+56,499
+0.3% +$3.87M 9.63% 3
2019
Q2 		$1.25B Sell
17,168,153
-642,029
-4% -$50.5M 8.99% 2
2019
Q1 		$1.44B Buy
17,810,182
+1,203,644
+7% +$98.5M 9.73% 2
2018
Q4 		$1.53B Buy
16,606,538
+952,014
+6% +$83.7M 11.02% 2
2018
Q3 		$1.48B Buy
15,654,524
+965,272
+7% +$91.5M 8.5% 3
2018
Q2 		$1.36B Buy
14,689,252
+1,203,008
+9% +$117M 7.56% 3
2018
Q1 		$1.28B Buy
13,486,244
+845,276
+7% +$92.9M 7.29% 3
2017
Q4 		$1.22B Sell
12,640,968
-562,956
-4% -$53.1M 7.18% 3
2017
Q3 		$1.17B Buy
13,203,924
+499,005
+4% +$38M 7.24% 2
2017
Q2 		$921M Buy
12,704,919
+3,340,038
+36% +$225M 5.79% 3
2017
Q1 		$610M Buy
9,364,881
+3,879,474
+71% +$244M 4.17% 6
2016
Q4 		$343M Buy
5,485,407
+579,378
+12% +$35.4M 2.46% 15
2016
Q3 		$309M Sell
4,906,029
-343,445
-7% -$22.2M 2.17% 13
2016
Q2 		$325M Buy
5,249,474
+316,606
+6% +$19.3M 2.47% 12
2016
Q1 		$282M Buy
+4,932,868
New +$275M 2.29% 13

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Orbis Allan Gray's ABBV Position: Q2 2022 in Review

Orbis Allan Gray sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 347,007 shares — an estimated $56.3M sold.

Orbis Allan Gray first reported a position in ABBV in Q1 2016 and held it in 25 quarters. The position peaked at $1.53B in Q4 2018. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

  • Orbis Allan Gray reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
  • Orbis Allan Gray sold 347,007 AbbVie shares in Q2 2022, an estimated $56.3M.
  • Orbis Allan Gray first reported a position in AbbVie in Q1 2016 and held it in 25 quarters.
  • Orbis Allan Gray's AbbVie position peaked at $1.53B in Q4 2018.
  • 3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Orbis Allan Gray's 13F filing for Q2 2022, filed 15 Aug 2022.